设为首页 加入收藏

TOP

CHLOROMYCETIN OTIC(chloramphenicol solution/drops)
2016-08-29 12:49:09 来源: 作者: 【 】 浏览:521次 评论:0

CHLOROMYCETIN OTIC - chloramphenicol solution/ drops 
Monarch Pharmaceuticals, Inc.

----------

 

 

WARNING

Bone marrow hypoplasia including aplastic anemia and death has been reported following local application of chloramphenicol. Chloramphenicol should not be used when less potentially dangerous agents would be expected to provide effective treatment.

 

Description

Each milliliter of Chloromycetin Otic contains 5 mg (0.5%) chloramphenicol in propylene glycol. Sterile.

The chemical names for chloramphenicol are:

 
Acetamide, 2,2-dichloro- N-[2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl) ethyl]-, and
D- threo-(—)-2,2-Dichloro-N-[ β,-hydroxy-α-(hydroxymethyl)- p-nitrophenethyl] acetamide.
 

Chloramphenicol has the following empirical and structural formulas:

ChemStructure1

 

Clinical Pharmacology

Chloramphenicol is a broad-spectrum antibiotic originally isolated from Streptomyces venezuelae. It is primarily bacteriostatic and acts by inhibition of protein synthesis by interfering with the transfer of activated amino acids from soluble RNA to ribosomes. Development of resistance to chloramphenicol can be regarded as minimal for staphylococci and many other species of bacteria.

 

Indications and Usage

Chloromycetin (chloramphenicol) Otic is indicated for the treatment of surface infections of the external auditory canal caused by susceptible strains of various gram-positive and gram-negative organisms including: Staphylococcus aureus, Escherichia coli, Hemophilus influenzae, Pseudomonas aeruginosa, Aerobacter aerogenes, Klebsiella pneumoniae and Proteus species.

Deeper infections should be treated with appropriate systemic antibiotics.

 

Contraindications

This product is contraindicated in persons sensitive to any of its components.

Perforated tympanic membrane is considered a contraindication to the use of any medication in the external ear canal.

 

Warnings

SEE BOXED WARNING.

Discontinue promptly if sensitization or irritation occurs.

 

Precautions

 

The prolonged use of antibiotics may occasionally result in overgrowth of nonsusceptible organisms, including fungi. If new infections appear during medication, the drug should be discontinued and appropriate measures should be taken.

In all serious infections, the topical use of chloramphenicol should be supplemented by appropriate systemic medication.

The possibility of the occurrence of ototoxicity must be considered if this product is allowed to enter the middle ear.

 

Adverse Reactions

Signs of local irritation with subjective symptoms of itching or burning, angioneurotic edema, urticaria, vesicular and maculopapular dermatitis have been reported in patients sensitive to chloramphenicol and are causes for discontinuing the medication. Similar sensitivity reactions to other materials in topical preparations may also occur. Blood dyscrasias have been reported in association with the use of chloramphenicol (see WARNINGS).

 

Dosage and Administration

Instill 2 or 3 drops into the affected ear three times daily.

 

How Supplied

NDC 61570-331-31

Chloromycetin (chloramphenicol) Otic is supplied in 15 mL vials with droppers.

 

Store below 30°C (86°F).

Chloromycetin, brand of chloramphenicol, Reg US Pat Off.

Rx only.

Rev. 12/98

Manufactured by: Parkedale Pharmaceuticals, Inc., Rochester, MI 48307

Distributed by:Monarch Pharmaceuticals, Inc., Bristol, TN 37620

 

LabelGraphics1

LabelGraphics1

CHLOROMYCETIN OTIC 
chloramphenicol solution/ drops
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:61570-331
Route of Administration AURICULAR (OTIC) DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
CHLORAMPHENICOL (CHLORAMPHENICOL) CHLORAMPHENICOL 5 mg  in 1 mL
Product Characteristics
Color      Score     
Shape   Size  
Flavor   Imprint Code  
Contains     
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:61570-331-31 15 mL in 1 VIAL None

Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA050205 03/30/1953 02/12/2002

Labeler - Monarch Pharmaceuticals, Inc. (809587413)
Establishment
Name Address ID/FEI Operations
Parkedale Pharmaceuticals, Inc   809587413 MANUFACTURE

Revised: 09/2011 Monarch Pharmaceuticals, Inc.  

以下是“全球医药”详细资料
Tags: 责任编辑:admin
】【打印繁体】【投稿】【收藏】 【推荐】【举报】【评论】 【关闭】 【返回顶部
分享到QQ空间
分享到: 
上一篇MEPRON (atovaquone) oral suspen.. 下一篇Nizoral® (ketoconazole) 2% ..

相关栏目

最新文章

图片主题

热门文章

推荐文章

相关文章

广告位